Catalona W J
Urology. 1981 Aug;18(2):113-7. doi: 10.1016/0090-4295(81)90417-9.
There is a highly significant correlation between specific red cell adherence (SRCA) tests for ABO(H) blood group antigens and the biologic potential of a bladder cancer in terms of both superficial tumor recurrences and the subsequent development of invasive cancer. The correlation with superficial recurrences is of limited practical value because almost one half of patients with antigen-positive tumors have superficial recurrences. Similarly, because in approximately one third of patients with SRCA-negative tumors invasive cancer does not develop, SRCA tests cannot be used to select patients for early cystectomy. Because invasive cancer proceeds to develop in less than 10 per cent of patients with high-grade, antigen-positive tumors, SRCA tests may be of use to identify patients with high-grade tumors who deserve a trial of conservative therapy. SRCA tests must be interpreted with caution in patients who have been treated previously with radiation therapy or thiotepa, in whom false positive tests may occur, and in patients with type O blood in whom false negative tests may occur.
ABO(H)血型抗原的特异性红细胞黏附（SRCA）检测与膀胱癌的生物学潜能之间存在高度显著的相关性，这体现在浅表肿瘤复发以及随后浸润性癌的发生方面。与浅表复发的相关性实际价值有限，因为几乎一半抗原阳性肿瘤患者会出现浅表复发。同样，由于约三分之一SRCA阴性肿瘤患者未发生浸润性癌，所以SRCA检测不能用于选择早期膀胱切除术的患者。由于不到10%的高级别、抗原阳性肿瘤患者会发展为浸润性癌，SRCA检测可能有助于识别值得进行保守治疗试验的高级别肿瘤患者。对于先前接受过放射治疗或噻替派治疗的患者，SRCA检测必须谨慎解读，这些患者可能会出现假阳性检测结果；对于O型血患者，可能会出现假阴性检测结果。
